medigraphic.com

2019, Number 1

Next >>

Rev Cuba Endoc 2019; 30 (1)

Guidelines for the diagnosis and treatment of osteoporosis, 2018

Language: Spanish
References: 53
Page: 1-45
PDF size: 648.14 Kb.


Text Extraction

No abstract.


REFERENCES

  1. Reyes Llerena Gil A, Guibert Toledano M, Penedo Coello A, Báez Dueñas R, et al. Community study based to estimate the prevalence and burden of illness of rheumatic diseases in Cuba. A COPCORD study. J Clin Rheumatol. 2009;15:51-5. doi: 10.1097/RHU.0b013e31819b61cb.

  2. Reyes Llerena Gil A, Guibert Toledano M. Rheumatology and care for rheumatic diseases in Cuba. J Clin Rheumatology. 1999;5(5):289-922.

  3. Reyes Llerena Gil A, Guibert Toledano M. Factores de riesgo asociados a osteoporosis y fracturas en población cubana. Rev Peruana de Reumatología. 2016;22:4-13.

  4. MINSAP. Oficina Nacional de Registros y Estadísticas 2016. Morbimortalidad por fracturas de caderas en Cuba. Años 2006-2015.

  5. Navarro Despaigne D. Estrógenos y huesos. En: Artiles L, Navarro D, Manzano BR, eds. Climaterio y menopausia, un enfoque desde lo social. La Habana: Editorial Científico Técnica; 2007. p. 202-15.

  6. Díaz López JB, Gómez Alonso C. Concepto de osteoporosis: masa ósea vs. calidad ósea. Actualizaciones en Osteoporosis. Madrid: Ergon; 2006. p. 3-18.

  7. Guías 2012 para el diagnóstico, la prevención y el tratamiento de la osteoporosis. Medicina, Buenos Aires. 2013;73:55-74.

  8. Mirza F, Canalis E, Secondary osteoporosis: pathophysiology and management. Eur J Endocrinol. 2015;173(3) R131-51.

  9. Fakruddin JM, Laurence J. HIV-1 enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity, Arch Virol, 2005;150(1):67-78.

  10. AL-Yin MT, Lund E, Shah J, Zhang CA, Foca M, Neu N, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS. 2014;28:345–53.

  11. Sax PE, Wohl D, Yin MT, Post F, De Jesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, co-formulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double- blind, phase 3, non-inferiority trials. Lancet. 2015;385 (9987):2606-15.

  12. European AIDS Clinical Society (EACS) Guidelines, Version 8, October 2015. Available at: http://www.eacsociety.org/files/2-english_rev-20151221.pdf Accessed 4 february 2016

  13. Navarro Despaigne D, Reyes Llerena Gil A. Guías nacionales para el diagnóstico y tratamiento de la osteoporosis. Soc. Cubana de Endocrinología, Soc. Cubana de Reumatología. 2014;25(1):1-34. Versión on line ISSN. 1561-2953. http://scielo.sld.cu

  14. Brown TT, Qaqish RB. Anti Retroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165-74.

  15. Schaefer HM. Long term management of the kidney transplant recipient. Blood Purif. 2012;33:205-11.

  16. Marcen R, Caballero C, Uriol O, Fernández A, Villafruela JJ, Pascual J, et al. Prevalence of Osteoporosis, osteopenia, and vertebral fractures in long-term renal trasplant recipients. Trasplant Proc. 2007;39(7):2256-58.

  17. Leavy B, Michaelsson K, Aberg Melhus H, Byberg L. The Impact of Disease and Drugs on Hip Fracture Risk. Calcif Tissue Int. 2017:100:1-12.

  18. Duany Navarro A, Navarro Despaigne DA. Puntos de encuentro entre depresión y osteoporosis. AMC. 2018 Feb [citado 2018 Jul 24];22(1):115-22. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-02552018000100015&lng=es

  19. Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. The National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017:12:43-60.

  20. Camacho P, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American association of clinical endocrinologists and american college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis. Endocrine Practice. 2016;22(Suppl 4);1-42.

  21. International Society Clinical Densitometry. 2013 Official Position-adult. Disponible en: www.iscd.org.official/positions/2013-iscd-org-official.positions-adult

  22. Servicio Central de Publicaciones del Gobierno Vasco. Osteoporosis postmenopáusica: un consenso necesario. INFAC. 2015;23(4):28-32.

  23. Granela Cortiñas K, Pérez Gesen C, Carvajal Martínez F, Navarro Despaigne D, Domínguez Alonso E, Díaz Horta O, et al. Mineralización ósea en niños y adolescentes con hipotiroidismo congénito. Rev Cubana Endocrinol. 2011;22:118-32.

  24. Navarro Despaigne DA. Osteoporosis en el hombre, un tema poco visible. Rev Cubana Endocrinol. 2017 Dic [citado 2018 Jul 24];28(3):1-9. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1561-29532017000300010&lng=es

  25. Farrerons Minguella J, Malouf J. Radiología de la fractura vertebral. Actualización en Osteoporosis. Madrid: Ergon; 2006. p. 29-43.

  26. Malgo F, Hamdy NAT, Ticheler ChJM, Smith F, Kroon HM, Rabelink TJ. Value and potential limitations of vertebral fracture assessment (VFA) compared to conventional spine radiography: experience from a fracture liaison service (FLS) and a meta-analysis. Osteoporos Int. 2017;28:2955-65.

  27. Genant HK, Li J, Wu CY, Shepherd JA. Vertebral fractures in osteoporosis: a new method for clinical assessment. J Clin Densitom. 2000;3:281-290.

  28. Waterloo S, Luai AA, Center JR, Eisman JA, Morseth B, Nguyen N, et al. Prevalence of vertebral fractures in women and men in the population-based Tromsø Study. BMC Musculoskeletal Disorders. 2012;13:3. Disponible en: http://www.biomedcentral.com/1471-2474/13/3

  29. Navarro D, Triana M. Efectos del kalsis como coadyuvante en el tratamiento de la baja masa ósea (osteopenia) en mujeres de edad mediana. Rev Colombiana de Menopausia. 2010;16:307-18.

  30. Leavy B, Michaelson K, Aberg AC, Melhus H, Byberg L. The Impact of Disease and Drugs on Hip Fracture Risk. Calcif Tissue Int. 2017;100:1-12. DOI 10.1007/s00223-016-0194-7

  31. Sánchez O, Navarro D. Conocimientos sobre osteoporosis: Tesis para optar por el Título de Máster en Investigaciones en climaterio y menopausia. Repositorio Tesis FAC Cmdte. Manuel Fajardo, 2014.

  32. Formulario Nacional de Medicamentos. Disponible en: http://instituciones.sld.cu/ hospmiguelenriquez/files/2016/05/Formulario-nacional-de-medicamentos.pdf Acceso 3 de junio 2018.

  33. Fernandes Moreira LD, Longo de Oliveira M, Lirani-Galvão AP, Villa Marin-Mio R, Nolasco dos Santos R, Lazaretti-Castro M. Physical exercise and osteoporosis: effects of different types of exercises on bone and physical function of postmenopausal women. Arq Bras Endocrinol Metab. 2014;58 (5);514-22.

  34. Body J, Bergmann P, Boonen S, Boutsen Y, Bruyere O, Devogelaer JP, et al. Non pharmacological management of osteoporosis: a consensus of the Belgian Bone Club. Osteoporos Int. 2011;22: 2769-88.

  35. Hiligsmann M, Ronda G, van der Weijden T, Boonen A. The development of a personalized patient education tool for decision making for postmenopausal women with osteoporosis. Osteoporos Int. 2016;27:2489-96.

  36. Actualización 2011. Consenso Sociedad Española de Reumatología de Osteoporosis. Reumatol Clin. 2011;7:357-79.

  37. Khosla S, Bilezikian JP, Dempster DW, Lewiecki EM, Miller PD, Neer RM, et al. Benefits and risks of bisphosphonate therapy for osteoporosis. J Clin Endocrinol Metab. 2012;97:2272-82.

  38. Curtis EM, Moon RJ, Dennison EM, Harvey NC, Cooper C. Recent Advances in the Pathogenesis and Treatment of Osteoporosis. Clin Med (Lond). 2016;16(4):360-4.

  39. Orwol E, Teglbjærg CS, Langdahl BL, Chapurlat R, Czerwinski E, Kendler DL, et al. A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab. 2012;97(9):3161-9.

  40. Wąsowski M, Proniewska-Sadowska M, Budzińska U. Bisphosphonates and denosumab – the efficacy in the fracture prevention. Post N Med. 2017;XXX(01):37-42.

  41. Posada AF, Aguirre HD, García Casallas JC, Lodoñ Patiño JD, Valle Oñate R. Nuevas terapias en osteoporosis. Rev Colombiana Reumatol. 2016;3(1):34-43.

  42. Diez-Pérez A, Naylor KM, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, et al. International Osteoporosis Foundation and European Calcified Tissue Society Working Group. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017;28 (3):767-74.

  43. NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis. Disponible en: www.shef.ac.uk/NOGG Acceso 4 de junio 2018.

  44. Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen K, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis & Rheumatology. 2017;69(8):1521-37.

  45. Weaver CM, Gordon CM, Janz KF, Kalkwarf HJ, Lappe JM, Lewis R, et al. The National Osteoporosis Foundation’s position statement on peak bone mass development and lifestyle factors: a systematic review and implementation recommendations. Osteoporos Int. 2016;27:4:1281-1386.

  46. Golds G, Houdek D, Arnason T. Male Hypogonadism and Osteoporosis: The effects, clinical consequences, and treatment of Testosterone deficiency in bone health. International J Endocrinol. 2017, Article ID 4602129, 15 pages. Disponible en: http://dx.doi.org/10.1155/2017/4602129

  47. Xu X, Jia X, Mo L, Liu Ch, Zheng L, Yuan Q, Zhou Z. Intestinal microbiota: a potential target for the treatment of postmenopausal osteoporosis. Bone Research. 2017;5: 17046. DOI: 10.1038/boneres.2017.46

  48. Boyce A, Gafni R, Approach to the child with fractures. J Clin Endocrinol Metab. 2011;96 (7):1943-52.

  49. National Institutes of Health Osteoporosis and Related Bone Diseases National Resource Center Juvenil Osteoporosis. Disponible en: https://www.bones.nih.gov/sites/ bones/files/juvenile_osteoporosis.pdf Acceso 4 junio 2018.

  50. Vierucci F, Saggese G, Cimaz R. Osteoporosis in childhood. Curr Opin Rheumatol. 2017;29:535-46. DOI:10.1097/BOR.0000000000000423

  51. Robledillo JC. Evaluación y tratamiento de la osteoporosis en niños. Disponible en: https://www.pediatriaintegral.es/publicacion-2017-04/evaluacion-y-tratamiento-de-la-osteoporosis-en-niños/ Acceso 11 de junio 2018.

  52. Yeste D, Clemente M, Campos A, Fábregas A, Soler L, Carrascosa A. Osteoporosis en pediatría. Encuentro con el experto. 39 Congreso de la Sociedad Española de Endocrinología Pediátrica. Rev Esp Endocrinol Pediatr. 2017;8(Suppl):73-85.

  53. Fernández García I, Bustamante Teijido M, Rodríguez Orta M, León Pérez S, García García A. Caso atípico de osteoporosis idiopática juvenil. Rev Cubana Pediatr. 2014 Jun [acceso 2018 Jun 11];86(1):108-14. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312014000100014&lng=es




2020     |     www.medigraphic.com